Park N H, Pavan-Langston D, McLean S L
J Infect Dis. 1979 Nov;140(5):802-6. doi: 10.1093/infdis/140.5.802.
The local and trigeminal ganglionic therapeutic efficacy of two topical and systemic antiviral drugs was studied in mouse lips inoculated with herpes simplex virus type 1 after thermal injury. Application of topical 3% acylovir (acycloguanosine) ointment three times daily for four days completely blocked the replication of virus in the lips, and the healing process was greatly accelerated compared with that in placebo-treated infected controls. However, neither the healing process nor the viral replication was influenced by similar therapy with 3% vidarabine ointment. When given systemically for four days, starting one day after inoculation, acyclovir (40-60 mg/kg per day) and vidarabine (50 mg/kg per day) significantly reduced the clinical manifestations on the lips and viral titers of cultures obtained from the lips. Establishment of viral latency in the trigeminal ganglion was significnatly inhibited by systemic acyclovir (60 mg/kg per day), whereas systemic vidarabine (50 mg/kg per day) was ineffective. These data suggest that acyclovir may be one of the most promising antiviral agents for the management of oral herpes viral infections and trigeminal ganglionic latency of virus as demonstrated in the mouse model.
在热损伤后接种1型单纯疱疹病毒的小鼠唇部，研究了两种局部和全身用抗病毒药物的局部及三叉神经节治疗效果。每天3次局部应用3%阿昔洛韦（无环鸟苷）软膏，持续4天，可完全阻断唇部病毒复制，与安慰剂治疗的感染对照组相比，愈合过程大大加速。然而，3%阿糖腺苷软膏的类似治疗对愈合过程和病毒复制均无影响。接种后1天开始连续4天全身给药时，阿昔洛韦（每天40 - 60 mg/kg）和阿糖腺苷（每天50 mg/kg）可显著减轻唇部的临床表现以及从唇部获得的培养物中的病毒滴度。全身应用阿昔洛韦（每天60 mg/kg）可显著抑制三叉神经节中病毒潜伏的建立，而全身应用阿糖腺苷（每天50 mg/kg）则无效。这些数据表明，在小鼠模型中，阿昔洛韦可能是治疗口腔疱疹病毒感染和病毒三叉神经节潜伏最有前景的抗病毒药物之一。
